{"preliminary_commentary":{"by_channel":{"x_thread":11},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06105632\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"FOURLIGHT-1","nct_id":"NCT06105632","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=fourlight-1-nct06105632. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"PF-07220060 to be taken by mouth as a tablet in combination with fulvestrant (a solution for injection)","label":"Arm A","type":"EXPERIMENTAL"},{"description":"Investigator's choice of therapy of either:\n\n* Fulvestrant alone (a solution for injection), or\n* Everolimus in combination with exemestane, both a tablet to be taken by mouth.","label":"Arm B","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-01-21","type":"ESTIMATED"},"conditions":["Advanced or Metastatic Breast Cancer"],"enrollment":{"count":333,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"PF-07220060 CDK4 inhibitor","otherNames":[],"type":"DRUG"},{"name":"Fulvestrant","otherNames":[],"type":"DRUG"},{"name":"Everolimus","otherNames":[],"type":"DRUG"},{"name":"Exemestane","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-20","lead_sponsor":"Pfizer","official_title":"AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 2 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR'S CHOICE OF THERAPY IN PARTICIPANTS AT LEAST 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY (FOURLIGHT-1)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-01-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) progression, as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1","timeFrame":"From Initiation up to 2 years"}],"references":[],"start_date":{"date":"2024-01-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","url":"https://clinicaltrials.gov/study/NCT06105632"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/fourlight-1-nct06105632"}